Brian P. Vickery, MD

Medical Instructor in the Department of Pediatrics

Department:
Pediatrics

Division:
Allergy and Immunology

Mailing Address:
DUMC 2644 Durham, NC 27710

Appointment Telephone:
919-684-9914

Office Telephone:
919-681-2949

Fax:
919-668-3750

Training:
MD, Medical College of Georgia School of Medicine, 2001

Fellowship:
Allergy and Clinical Immunology, Yale University School of Medicine (Connecticut), 2005-2008

Residency:
Pediatrics, New York-Presbyterian Hospital, Cornell Campus, 2001-2005

Clinical Interests:
Care of children with allergic and immunologic disorders, especially food allergy, atopic dermatitis, and anaphylaxis

Research Interests:
I am interested in the relevant mechanistic and clinical aspects of the rising prevalence in atopic disorders. Of particular concern is the relatively recent surge in IgE-mediated and non-IgE mediated food hypersensitivity. The development of interventional strategies to reverse this trend with the induction of tolerance is a major translational research interest. During fellowship, my research in the laboratory of Professor Kim Bottomly focused on the role of Toll-like receptor signaling in the dendritic cell response to peanut allergens. This work was part of a larger effort within the Consortium for Food Allergy Research (CoFAR) to develop innovative treatments for IgE-mediated human food allergy. Here at Duke, I am continuing that effort as part of Dr. Wesley Burks' research team, concentrating on oral immunotherapy (OIT) for food allergy in children. I am the principal investigator in the DEVIL (Determining Efficacy and Value of Immunotherapy in the Likelihood of peanut tolerance) study, which assesses the impact of high and low dose peanut OIT in recently diagnosed peanut-allergic children aged 9-36 months. In addition to the clinical outcome of oral tolerance to peanut, the DEVIL study will profile high resolution longitudinal changes in peanut epitope-specific B and T cell responses. A broader long term goal is to understand the role of OIT-induced toleragenic changes and apply them towards primary prevention strategies.

In addition, I am currently the site PI for a multicenter trial of reslizumab, a novel anti-interleukin-5 monoclonal antibody, for the treatment of eosinophilic esophagitis in children 5-18, as well as a co-investigator in several studies with the Asthma Clinical Research Centers of the American Lung Association.

Publications:
Vickery BP, Burks AW. Immunotherapy in the treatment of food allergy: focus on oral tolerance.  Curr Opin Allergy Clin Immunol.  2009 May 28.

Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW. Clinical efficacy and immune regulation with peanut oral immunotherapy.  J Allergy Clin Immunol.  2009 Jul 2.

Vickery BP. Skin barrier function in atopic dermatitis.  Curr Opin Pediatr.  2007 Feb;19(1):89-93.